PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
First in Patient Study for PF-06840003 in Malignant Gliomas
- Conditions
- OligodendrogliomaMalignant GliomaAstrocytoma
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT02764151
- Locations
- 🇺🇸
UCLA Clinical & Translational Research Center, Los Angeles, California, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers
- Conditions
- Fever
- Interventions
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 290
- Registration Number
- NCT02761980
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT02757625
- Locations
- 🇯🇵
Asahikawa Medical University Hospital, Asahikawa, Hokkaido, Japan
🇯🇵Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan
A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT02746926
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
- Conditions
- Atopic DermatitisChronic Rhinosinusitis With Nasal PolypsHealthy
- Interventions
- Biological: PF-06817024Other: Placebo for PF-06817024
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2022-05-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 97
- Registration Number
- NCT02743871
- Locations
- 🇺🇸
UC Davis Dermatology, Sacramento, California, United States
🇺🇸UC Davis CTSC Clinical Research Center, Sacramento, California, United States
🇺🇸New Haven Clinical Research Unit, New Haven, Connecticut, United States
Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study
- Conditions
- Hemophilia BHemophilia A
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT02740413
Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT02732938
- Locations
- 🇺🇸
Wayne Memorial Hospital, Goldsboro, North Carolina, United States
🇺🇸Southeastern Medical Oncology Center, Jacksonville, North Carolina, United States
🇺🇸MUSC Health North Charleston, North Charleston, South Carolina, United States
Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
- Conditions
- Low Back Pain
- Interventions
- Biological: Tanezumab 10 mgBiological: Tanezumab 5 mgBiological: Placebo for tanezumab
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 277
- Registration Number
- NCT02725411
- Locations
- 🇯🇵
Meitoh Hospital, Nagoya, Aichi, Japan
🇯🇵Asahi General Hospital, Asahi, Chiba, Japan
🇯🇵Fukuoka Mirai Hospital, Higashi-ku,Fukuoka, Fukuoka, Japan
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
- Conditions
- Clostridium Difficile Associated Disease
- Interventions
- Biological: Clostridium difficile VaccineBiological: Placebo
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT02725437
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital (formerly Medical Co. LTA Sumida Hospital), Sumida-ku, Tokyo, Japan
🇯🇵SOUSEIKAI PS Clinic (formerly Medical Co. LTA PS Clinic), Fukuoka, Japan
Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
- Conditions
- Hemophilia A
- Interventions
- Drug: Refacto AF
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Pfizer
- Registration Number
- NCT02718677